ABILIFY There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. | Atypical antipsychotic | caution |
ABILIFY ASIMTUFII Pregnancy Category C: Aripiprazole crosses the placenta and may cause extrapyramidal symptoms or withdrawal in neonates. Use only if potential benefit justifies risk to the fetus. | Atypical antipsychotic | caution |
ABILIFY MAINTENA KIT Use during pregnancy only if potential benefit justifies potential risk to fetus; may cause extrapyramidal and/or withdrawal symptoms in neonates. | Atypical antipsychotic | caution |
ABILIFY MYCITE KIT Comprehensive clinical and safety monograph for ABILIFY MYCITE KIT (ABILIFY MYCITE KIT). | Atypical antipsychotic | caution |
ADASUVE Comprehensive clinical and safety monograph for ADASUVE (ADASUVE). | Antipsychotic | caution |
ALPHAZINE Comprehensive clinical and safety monograph for ALPHAZINE (ALPHAZINE). | Antipsychotic | caution |
ARIPIPRAZOLE Strong CYP3A4 inhibitors (eg ketoconazole) or inducers (eg carbamazepine) require dose adjustment May cause suicidal thoughts and metabolic changes including weight gain and dyslipidemia. | Atypical Antipsychotic | safe |
ARISTADA Comprehensive clinical and safety monograph for ARISTADA (ARISTADA). | Atypical Antipsychotic | caution |
ARISTADA INITIO KIT Comprehensive clinical and safety monograph for ARISTADA INITIO KIT (ARISTADA INITIO KIT). | Atypical Antipsychotic | caution |
ASENAPINE MALEATE Strong CYP1A2 inhibitors like fluvoxamine increase asenapine levels Sublingual administration food and drink can decrease absorption May cause cerebrovascular events in elderly patients with dementia. | Atypical Antipsychotic | safe |
BREXPIPRAZOLE Strong CYP3A4 or CYP2D6 inhibitors require dose adjustment May cause suicidal thoughts and metabolic changes including weight gain and dyslipidemia. | Atypical Antipsychotic | safe |
CAPLYTA Comprehensive clinical and safety monograph for CAPLYTA (CAPLYTA). | Atypical Antipsychotic | caution |
CARIPRAZINE HYDROCHLORIDE Comprehensive clinical and safety monograph for CARIPRAZINE HYDROCHLORIDE (CARIPRAZINE HYDROCHLORIDE). | Atypical Antipsychotic | caution |
CHLORPROMAZINE HYDROCHLORIDE Comprehensive clinical and safety monograph for CHLORPROMAZINE HYDROCHLORIDE (CHLORPROMAZINE HYDROCHLORIDE). | Antipsychotic | caution |
CHLORPROMAZINE HYDROCHLORIDE INTENSOL Comprehensive clinical and safety monograph for CHLORPROMAZINE HYDROCHLORIDE INTENSOL (CHLORPROMAZINE HYDROCHLORIDE INTENSOL). | Antipsychotic | caution |
CLOZAPINE Bone marrow suppressants may increase risk of agranulocytosis Can cause severe neutropenia and agranulocytosis requiring mandatory WBC monitoring. | Atypical Antipsychotic | safe |
CLOZARIL Comprehensive clinical and safety monograph for CLOZARIL (CLOZARIL). | Atypical Antipsychotic | caution |
COMPAZINE Comprehensive clinical and safety monograph for COMPAZINE (COMPAZINE). | Antipsychotic (Phenothiazine) / Antiemetic | caution |
DAPIPRAZOLE HYDROCHLORIDE Comprehensive clinical and safety monograph for DAPIPRAZOLE HYDROCHLORIDE (DAPIPRAZOLE HYDROCHLORIDE). | Atypical Antipsychotic | caution |
DROPERIDOL Other QT-prolonging agents increase risk of torsades de pointes Can cause QT prolongation and severe hypotension. | Antipsychotic | safe |
ETRAFON 2-10 Comprehensive clinical and safety monograph for ETRAFON 2-10 (ETRAFON 2-10). | Antipsychotic/Antidepressant Combination | caution |
ETRAFON 2-25 Comprehensive clinical and safety monograph for ETRAFON 2-25 (ETRAFON 2-25). | Antipsychotic/Antidepressant Combination | caution |
ETRAFON-A Comprehensive clinical and safety monograph for ETRAFON-A (ETRAFON-A). | Antipsychotic/Antidepressant Combination | caution |
ETRAFON-FORTE Comprehensive clinical and safety monograph for ETRAFON-FORTE (ETRAFON-FORTE). | Antipsychotic/Antidepressant Combination | caution |
FANAPT Comprehensive clinical and safety monograph for FANAPT (FANAPT). | Atypical Antipsychotic | caution |
FAZACLO ODT Comprehensive clinical and safety monograph for FAZACLO ODT (FAZACLO ODT). | Atypical Antipsychotic | caution |
FLUPHENAZINE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
FLUPHENAZINE DECANOATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
FLUPHENAZINE HCL CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
FLUPHENAZINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
GEODON Comprehensive clinical and safety monograph for GEODON (GEODON). | Atypical Antipsychotic | caution |
HALDOL Comprehensive clinical and safety monograph for HALDOL (HALDOL). | Antipsychotic | caution |
HALDOL SOLUTAB Comprehensive clinical and safety monograph for HALDOL SOLUTAB (HALDOL SOLUTAB). | Antipsychotic | caution |
HALOPERIDOL DECANOATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and QT prolongation. | Typical Antipsychotic | safe |
HALOPERIDOL INTENSOL CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and QT prolongation. | Typical Antipsychotic | safe |
HALOPERIDOL LACTATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and QT prolongation. | Typical Antipsychotic | safe |
ILOPERIDONE Strong CYP2D6 or CYP3A4 inhibitors require dose adjustment Can cause orthostatic hypotension and QT prolongation. | Atypical Antipsychotic | safe |
INAPSINE Comprehensive clinical and safety monograph for INAPSINE (INAPSINE). | Antipsychotic | caution |
INNOVAR Comprehensive clinical and safety monograph for INNOVAR (INNOVAR). | Antipsychotic (Butyrophenone) | caution |
INVEGA Comprehensive clinical and safety monograph for INVEGA (INVEGA). | Atypical Antipsychotic | caution |
INVEGA HAFYERA Comprehensive clinical and safety monograph for INVEGA HAFYERA (INVEGA HAFYERA). | Atypical Antipsychotic | caution |
INVEGA SUSTENNA Comprehensive clinical and safety monograph for INVEGA SUSTENNA (INVEGA SUSTENNA). | Atypical Antipsychotic | caution |
INVEGA TRINZA Comprehensive clinical and safety monograph for INVEGA TRINZA (INVEGA TRINZA). | Atypical Antipsychotic | caution |
LATUDA Comprehensive clinical and safety monograph for LATUDA (LATUDA). | Atypical Antipsychotic | caution |
LEVOPROME Comprehensive clinical and safety monograph for LEVOPROME (LEVOPROME). | Phenothiazine Antipsychotic | caution |
LOXAPINE SUCCINATE Comprehensive clinical and safety monograph for LOXAPINE SUCCINATE (LOXAPINE SUCCINATE). | Antipsychotic | caution |
LOXITANE Comprehensive clinical and safety monograph for LOXITANE (LOXITANE). | Antipsychotic | caution |
LOXITANE C Comprehensive clinical and safety monograph for LOXITANE C (LOXITANE C). | Antipsychotic | caution |
LOXITANE IM Comprehensive clinical and safety monograph for LOXITANE IM (LOXITANE IM). | Antipsychotic | caution |
LUMATEPERONE Comprehensive clinical and safety monograph for LUMATEPERONE (LUMATEPERONE). | Atypical Antipsychotic | caution |
LUMATEPERONE TOSYLATE Comprehensive clinical and safety monograph for LUMATEPERONE TOSYLATE (LUMATEPERONE TOSYLATE). | Atypical Antipsychotic | caution |
LURASIDONE HYDROCHLORIDE Strong CYP3A4 inhibitors and inducers are contraindicated Can cause somnolence and akathisia. | Atypical Antipsychotic | safe |
LYBALVI Comprehensive clinical and safety monograph for LYBALVI (LYBALVI). | Atypical Antipsychotic | caution |
LYPQOZET Comprehensive clinical and safety monograph for LYPQOZET (LYPQOZET). | Antipsychotic | caution |
MELLARIL Comprehensive clinical and safety monograph for MELLARIL (MELLARIL). | Antipsychotic | caution |
MELLARIL-S Comprehensive clinical and safety monograph for MELLARIL-S (MELLARIL-S). | Antipsychotic | caution |
MILPROSA Comprehensive clinical and safety monograph for MILPROSA (MILPROSA). | Antipsychotic | caution |
MOBAN Comprehensive clinical and safety monograph for MOBAN (MOBAN). | Antipsychotic | caution |
MOLINDONE HYDROCHLORIDE Comprehensive clinical and safety monograph for MOLINDONE HYDROCHLORIDE (MOLINDONE HYDROCHLORIDE). | Antipsychotic | caution |
NAVANE Comprehensive clinical and safety monograph for NAVANE (NAVANE). | Antipsychotic, Typical | caution |
NUPLAZID Comprehensive clinical and safety monograph for NUPLAZID (NUPLAZID). | Atypical Antipsychotic | caution |
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause metabolic changes including weight gain hyperlipidemia and hyperglycemia. | Atypical Antipsychotic | safe |
OPIPZA Comprehensive clinical and safety monograph for OPIPZA (OPIPZA). | Antipsychotic (Atypical) | caution |
ORAP Comprehensive clinical and safety monograph for ORAP (ORAP). | Antipsychotic | caution |
PALIPERIDONE Strong CYP3A4 or P-gp inducers may decrease levels Can cause QT prolongation and orthostatic hypotension. | Atypical Antipsychotic | safe |
PALIPERIDONE PALMITATE Strong CYP3A4 or P-gp inducers may decrease levels Can cause QT prolongation and orthostatic hypotension. | Atypical Antipsychotic | safe |
PERMITIL Comprehensive clinical and safety monograph for PERMITIL (PERMITIL). | Antipsychotic | caution |
PERPHENAZINE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
PERSERIS KIT Comprehensive clinical and safety monograph for PERSERIS KIT (PERSERIS KIT). | Antipsychotic | caution |
PIMOZIDE Strong CYP3A4 inhibitors are contraindicated due to risk of QT prolongation Can cause QT prolongation and extrapyramidal symptoms. | Typical Antipsychotic | safe |
PROCHLORPERAZINE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic / Antiemetic | safe |
PROCHLORPERAZINE EDISYLATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic / Antiemetic | safe |
PROCHLORPERAZINE MALEATE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic / Antiemetic | safe |
PROKETAZINE Comprehensive clinical and safety monograph for PROKETAZINE (PROKETAZINE). | Phenothiazine Antipsychotic | caution |
PROLIXIN Comprehensive clinical and safety monograph for PROLIXIN (PROLIXIN). | Antipsychotic (Phenothiazine) | caution |
PROLIXIN DECANOATE Comprehensive clinical and safety monograph for PROLIXIN DECANOATE (PROLIXIN DECANOATE). | Antipsychotic | caution |
PROLIXIN ENANTHATE Comprehensive clinical and safety monograph for PROLIXIN ENANTHATE (PROLIXIN ENANTHATE). | Antipsychotic | caution |
PROMAPAR Comprehensive clinical and safety monograph for PROMAPAR (PROMAPAR). | Antipsychotic | caution |
PROMAZINE HYDROCHLORIDE Comprehensive clinical and safety monograph for PROMAZINE HYDROCHLORIDE (PROMAZINE HYDROCHLORIDE). | Antipsychotic | caution |
Quetiapine Atypical antipsychotic used for schizophrenia, bipolar disorder, and as an adjunct in treatment-resistant depression. Registry data and cohort studies involving thousands of first-trimester exposures do not demonstrate a consistent pattern of major congenital malformations. However, neonates exposed near delivery can develop extrapyramidal symptoms and neonatal withdrawal syndrome. Associated with gestational diabetes due to metabolic effects. Untreated psychosis or bipolar disorder in pregnancy carries serious maternal and fetal risks. | Atypical Antipsychotic | caution |
QUETIAPINE FUMARATE Strong CYP3A4 inhibitors may increase levels Can cause sedation cataracts and metabolic changes. | Atypical Antipsychotic | safe |
QUIDE Comprehensive clinical and safety monograph for QUIDE (QUIDE). | Antipsychotic | caution |
REXULTI Comprehensive clinical and safety monograph for REXULTI (REXULTI). | Atypical Antipsychotic | caution |
RISPERDAL Comprehensive clinical and safety monograph for RISPERDAL (RISPERDAL). | Atypical Antipsychotic | caution |
RISPERDAL CONSTA Comprehensive clinical and safety monograph for RISPERDAL CONSTA (RISPERDAL CONSTA). | Atypical Antipsychotic | caution |
RISPERIDONE Strong CYP2D6 inhibitors may increase levels Can cause hyperprolactinemia and metabolic changes. | Atypical Antipsychotic | safe |
RISVAN Comprehensive clinical and safety monograph for RISVAN (RISVAN). | Atypical Antipsychotic | caution |
SAPHRIS Comprehensive clinical and safety monograph for SAPHRIS (SAPHRIS). | Atypical Antipsychotic | caution |
SECUADO Comprehensive clinical and safety monograph for SECUADO (SECUADO). | Atypical Antipsychotic | caution |
SEPHIENCE Comprehensive clinical and safety monograph for SEPHIENCE (SEPHIENCE). | Atypical Antipsychotic | caution |
SERENTIL Comprehensive clinical and safety monograph for SERENTIL (SERENTIL). | Antipsychotic | caution |
SEROQUEL Comprehensive clinical and safety monograph for SEROQUEL (SEROQUEL). | Atypical Antipsychotic | caution |
SEROQUEL XR Comprehensive clinical and safety monograph for SEROQUEL XR (SEROQUEL XR). | Atypical Antipsychotic | caution |
SEZABY Comprehensive clinical and safety monograph for SEZABY (SEZABY). | Atypical Antipsychotic | caution |
SONAZINE Comprehensive clinical and safety monograph for SONAZINE (SONAZINE). | Antipsychotic | caution |
SPARINE Comprehensive clinical and safety monograph for SPARINE (SPARINE). | Antipsychotic | caution |
STELAZINE Comprehensive clinical and safety monograph for STELAZINE (STELAZINE). | Phenothiazine Antipsychotic | caution |
SYLEVIA Comprehensive clinical and safety monograph for SYLEVIA (SYLEVIA). | Atypical Antipsychotic | caution |
SYMBYAX Comprehensive clinical and safety monograph for SYMBYAX (SYMBYAX). | Antidepressant/Antipsychotic Combination | caution |
TARACTAN Comprehensive clinical and safety monograph for TARACTAN (TARACTAN). | Typical Antipsychotic | caution |
THIORIDAZINE HYDROCHLORIDE Strong CYP2D6 inhibitors are contraindicated due to risk of QT prolongation Can cause QT prolongation and retinopathy. | Typical Antipsychotic | safe |
THIORIDAZINE HYDROCHLORIDE INTENSOL Strong CYP2D6 inhibitors are contraindicated due to risk of QT prolongation Can cause QT prolongation and retinopathy. | Typical Antipsychotic | safe |
THIOTHIXENE Comprehensive clinical and safety monograph for THIOTHIXENE (THIOTHIXENE). | Typical Antipsychotic | caution |
THIOTHIXENE HYDROCHLORIDE Comprehensive clinical and safety monograph for THIOTHIXENE HYDROCHLORIDE (THIOTHIXENE HYDROCHLORIDE). | Typical Antipsychotic | caution |
THIOTHIXENE HYDROCHLORIDE INTENSOL Comprehensive clinical and safety monograph for THIOTHIXENE HYDROCHLORIDE INTENSOL (THIOTHIXENE HYDROCHLORIDE INTENSOL). | Typical Antipsychotic | caution |
THORAZINE Comprehensive clinical and safety monograph for THORAZINE (THORAZINE). | Typical Antipsychotic | caution |
TINDAL Comprehensive clinical and safety monograph for TINDAL (TINDAL). | Antipsychotic | caution |
TOVALT ODT Comprehensive clinical and safety monograph for TOVALT ODT (TOVALT ODT). | Atypical Antipsychotic | caution |
TREMIN Comprehensive clinical and safety monograph for TREMIN (TREMIN). | Antipsychotic | caution |
TRIAVIL 2-10 Comprehensive clinical and safety monograph for TRIAVIL 2-10 (TRIAVIL 2-10). | Antidepressant-Antipsychotic Combination | caution |
TRIAVIL 2-25 Comprehensive clinical and safety monograph for TRIAVIL 2-25 (TRIAVIL 2-25). | Antidepressant-Antipsychotic Combination | caution |
TRIAVIL 4-10 Comprehensive clinical and safety monograph for TRIAVIL 4-10 (TRIAVIL 4-10). | Antidepressant-Antipsychotic Combination | caution |
TRIAVIL 4-25 Comprehensive clinical and safety monograph for TRIAVIL 4-25 (TRIAVIL 4-25). | Antidepressant-Antipsychotic Combination | caution |
TRIAVIL 4-50 Comprehensive clinical and safety monograph for TRIAVIL 4-50 (TRIAVIL 4-50). | Antidepressant-Antipsychotic Combination | caution |
TRIFLUOPERAZINE HCL CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
TRIFLUOPERAZINE HYDROCHLORIDE CNS depressants may enhance sedative effects Can cause extrapyramidal symptoms and neuroleptic malignant syndrome. | Typical Antipsychotic | safe |
TRILAFON Comprehensive clinical and safety monograph for TRILAFON (TRILAFON). | Phenothiazine Antipsychotic | caution |
UZEDY Comprehensive clinical and safety monograph for UZEDY (UZEDY). | Atypical Antipsychotic | caution |
VERSACLOZ Comprehensive clinical and safety monograph for VERSACLOZ (VERSACLOZ). | Atypical Antipsychotic | caution |
VESPRIN Comprehensive clinical and safety monograph for VESPRIN (VESPRIN). | Antipsychotic | caution |
VRAYLAR Comprehensive clinical and safety monograph for VRAYLAR (VRAYLAR). | Atypical Antipsychotic | caution |
ZIPRASIDONE HYDROCHLORIDE Other drugs that prolong the QT interval are contraindicated Can cause QT prolongation and rash. | Atypical Antipsychotic | safe |
ZIPRASIDONE MESYLATE Other drugs that prolong the QT interval are contraindicated Can cause QT prolongation and rash. | Atypical Antipsychotic | safe |
ZUMANDIMINE Comprehensive clinical and safety monograph for ZUMANDIMINE (ZUMANDIMINE). | Antipsychotic | caution |
ZYPREXA Comprehensive clinical and safety monograph for ZYPREXA (ZYPREXA). | Atypical Antipsychotic | caution |
ZYPREXA RELPREVV Comprehensive clinical and safety monograph for ZYPREXA RELPREVV (ZYPREXA RELPREVV). | Atypical Antipsychotic | caution |
ZYPREXA ZYDIS Comprehensive clinical and safety monograph for ZYPREXA ZYDIS (ZYPREXA ZYDIS). | Atypical Antipsychotic | caution |
